Avidity Biosciences

42 articles with Avidity Biosciences

• Avidity Biosciences Announces Updates on the Pipeline and Platform at Virtual Investor and Analyst Event

  5/19/2021

  AOC 1001 demonstrated favorable safety profile in GLP toxicology studies - remains on track to initiate clinical studies in 2H 2021 AOC 1044 named as the clinical development candidate for DMD Avidity to live video webcast investor and analyst event today at 8:00 am PT / 11:00 am ET

• Avidity Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights

  5/12/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the first quarter ended March 31, 2021 and highlighted recent corporate progress.       

• 

  Lilly Intensifies RNA-Focused Drug Development with MiNA Therapeutics' saRNA Platform

  5/11/2021

  Eli Lilly announced a drug development collaboration with MiNA Therapeutics Limited focusing on five novel drug candidates that could be worth up to $245 million.

• Avidity Biosciences to Host Virtual Investor and Analyst Event on May 19, 2021

  5/3/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it will host a virtual investor and analyst event focused on the company's AOC platform on Wednesday, May 19, 2021, from 8:00 a.m. to 10:00 a.m. PT/11:00 a.m. to 1:00 p.m. ET.

• Avidity Biosciences to Present Oral Presentation on AOC 1001 for DM1 at American Academy of Neurology (AAN) 2021 Virtual Annual Meeting

  4/16/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that preclinical data for their lead candidate, AOC 1001 in development for myotonic dystrophy type 1 (DM1), will be presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting

• Avidity Biosciences to Participate in Upcoming Investor Conferences

  3/25/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that management will be participating in the following virtual investor conferences: Guggenheim Healthcare Talks—Genomic Medicines

• Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights

  3/15/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate progress.       

• 

  BioSpace Movers & Shakers, Feb. 19

  2/19/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Avidity Biosciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference

  2/17/2021

   Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that Sarah Boyce , President and Chief Executive Officer, and Art Levin , Ph.D., Chief Scientific Officer, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday,

• Avidity Biosciences Appoints W. Michael Flanagan, Ph.D. as Chief Technical Officer

  1/21/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of W. Michael Flanagan, Ph.D. as Chief Technical Officer

• 

  Avidity Prepares to Transition into Clinical Company in 2021

  1/21/2021

  California-based Avidity Biosciences has a goal of disrupting the way RNA-based therapies are delivered to patients through its Antibody-Oligonucleotide Conjugates (AOCs) platform.

• Avidity Biosciences Announces Changes to its Board of Directors

  1/11/2021

  Tamar Thompson and Jean Kim appointed to Board of Directors replacing Todd Brady and Michael Martin

• Avidity Biosciences Announces 2021 Pipeline Updates and Research Collaboration with MyoKardia

  1/8/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced pipeline updates for 2021 and a research collaboration with MyoKardia, Inc., a wholly-owned subsidiary of Bristol Myers Squibb.

• Avidity Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

  12/22/2020

   Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that Sarah Boyce , President and Chief Executive Officer, is scheduled to present at the 39 th Annual J.P. Morgan Healthcare Confer

• Avidity Biosciences Announced Addition to the Nasdaq Biotechnology Index

  12/21/2020

   Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), which became effective prior to market open on Monday, Decembe

• Avidity Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights

  11/10/2020

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the quarter ended September 30, 2020 and highlighted recent corporate progress.  

• Avidity Biosciences to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020

  11/5/2020

  Avidity Biosciences, Inc. announced that Sarah Boyce, President and Chief Executive Officer, will be presenting at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020 on Thursday, November 12th, 2020 at 8:45am PST.

• Avidity Biosciences to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020

  9/28/2020

  - Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that Sarah Boyce , President and Chief Executive Officer, Arthur Levin , Ph.D., Chief Scientific Officer, and Mike MacLean , Chi

• Avidity Biosciences to Present at Several Upcoming Virtual Scientific Meetings

  9/14/2020

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will present at several upcoming virtual scientific meetings.

• Avidity Biosciences Enters into Collaboration to Study the Natural History of Myotonic Dystrophy Type 1

  9/8/2020

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced it entered into a collaboration supporting END-DM1, a natural history study to advance the understanding of disease progression in patients w